Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder

LISA MANIG, STEFAN JANSSEN, STEVEN E SCHILD and DIRK RADES
In Vivo May 2017, 31 (3) 435-438;
LISA MANIG
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFAN JANSSEN
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEVEN E SCHILD
2Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIRK RADES
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rades.dirk@gmx.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: To develop an instrument that could estimate the 1-year survival probabilities of patients irradiated for recurrent carcinoma of the bladder. Patients and Methods: Thirty patients irradiated for locally recurrent bladder carcinoma were included. Six pre-treatment factors [age, gender, Karnofsky score (KPS), pack years, grading and time between cancer diagnosis and radiotherapy] were evaluated for survival. Of those factors showing a trend or significance on multivariate analysis, 1-year survival rates were added. Results: On multivariate analysis, KPS was significant (hazard ratio(HR)=3.76, p=0.008), age showed a trend (HR=2.04, p=0.13). Patient scores were five, nine, ten or fourteen points with 1-year survival rates of 13%, 25%, 57% and 82% (p=0.003). Three groups were designed, A (5-9 points), B (10 points) and C (14 points) with 1-year survival rates of 17%, 57% and 82% (p=0.001). Conclusion: This score, including three groups with different 1-year survival probabilities, can aid physicians treating patients with recurrent bladder carcinoma.

  • Locally recurrent carcinoma of the bladder
  • irradiation
  • pre-treatment factors
  • predictive score
  • survival

Carcinomas of the urinary bladder are uncommon compared to many other tumor entities (1). Up to more than 50% of patients develop a local recurrence following primary treatment of bladder carcinoma (1-3). In this situation, many patients receive trans-urethral resection of the recurrent tumor followed by local radiotherapy or chemo-radiation rather than radical cystectomy in order to preserve the urinary bladder (2). Generally, patients treated for recurrent malignant disease have a worse prognosis than those receiving primary treatment. The prognoses of patients with a recurrent carcinoma of the bladder may be improved with modern systemic treatments and radiation techniques (4-7).

Another approach that has gained importance in anticancer treatment during recent years includes the personalization of the treatment (8-10). This approach aims to provide optimal treatment for single patients by considering their individual situation including personal needs and resources. When aiming to administer a personalized treatment regimen, treating physicians are also strongly recommended to take into consideration the patient's remaining survival time. Thus, it is quite important to be able to judge this time as precisely as possible before assigning the patient to a specific treatment program. In order to support physicians in this aspect, many survival scores have become available during the last decade, mainly for patients requiring irradiation for metastatic disease (11-17). However, since many patients irradiated for recurrent carcinoma of the bladder have a limited prognosis, it appears reasonable to create a survival score also for this particular group.

Therefore, this study was conducted aiming to develop exactly such a tool to support physicians when they aim to select the optimal treatment program for a patient presenting with a locally recurrent carcinoma of the bladder.

Patients and Methods

The data of 30 patients who were treated with conventional radiotherapy alone or in combination with radio-sensitizing chemotherapy for locally recurrent carcinoma of the urinary bladder were analyzed with respect to a possible relation to survival. Sixteen patients (53%) received conventionally-fractionated radiotherapy with five times 1.8 Gy per week up to 59.4 Gy and fourteen patients additional chemotherapy. Pre-treatment factors included in the survival analyses were age, gender, Karnofsky score (KPS), number of pack years, grading of the recurrent tumor and time between cancer diagnosis and radiotherapy of the locally recurrent tumor (Table I).

Survival analyses were conducted with the Kaplan–Meier analysis plus the log-rank test. The pre-treatment factors achieving significance on these analyses (p<0.05) were additionally analyzed for independent associations with survival with the Cox proportional hazards model. Factors that showed at least a trend (p<0.15) were used for the predictive score. One-year survival rates of these factors given in percent were divided by 10 (factor scores). To calculate a patient's survival score, the factor scores were summed up. Higher scores were associated with better 1-year survival rates.

Results

Two of the evaluated six pre-treatment factors, patient age and KPS, showed significant relations to survival on univariate analyses (Table I). On the additional multivariate analysis, the KPS was also significant (hazard ratio(HR)=3.76, 95% confidence interval(CI)=1.42-10.42, p=0.008), and age showed a trend (HR=2.04, 95% CI=0.81-5.41, p=0.13). Therefore, both factors were used in the scoring tool.

Based on 1-year survival rates, the scoring points obtained for age were 3 points (age ≤76 years) and 7 points (age ≥77 years), respectively. And the scoring points for the KPS were 2 points (KPS ≤70) and 7 points (KPS >70), respectively. Thus, patients' survival scores were 5, 9, 10 or 14 points. The corresponding 1-year survival rates were 13%, 25%, 57% and 82%, respectively (p=0.003, Figure 1). Corresponding median survival times were 6.5 months, 5 months, 18 months and >80 months (median not reached during the follow-up period of more than 80 months), respectively.

Taking into account these survival data, 5 and 9 points were combined to one prognostic group as their median survivals were similar. Thus, three prognostic groups were designed, group A (5-9 points), group B (10 points) and group C (14 points), with 1-year survival rates of 17%, 57% and 82%, respectively (p=0.001, Figure 2). The corresponding median survival times were 5.5 months, 18 months and >80 months (median not reached during follow-up period), respectively.

Discussion

To be able to provide the best possible treatment program for an individual patient with recurrent carcinoma of the bladder, it is crucial to have a precise estimate of the patient's remaining lifespan. In patients with a short remaining time, a long program of treatment and aggressive approaches should likely be avoided. In patients identified as long-term survivors, the risk of treatment-related late morbidity gains importance. When patients are assigned to radiotherapy, this means that long-term survivors appear better treated with lower doses per fraction, because the risk of late morbidity has been reported to be greater with higher doses per fraction. Moreover, radiotherapy with higher total doses often results in better outcomes in terms of local disease control and survival, which has been reported for different situation such as metastases to the brain (18-20). Therefore, when aiming to deliver personalized cancer treatment, one should include the corresponding patient's survival prognosis in the decision process. This applies also to patients with a locally recurrent carcinoma of the bladder. Like for other cancer types and situations, a scoring tool for estimating the survival time of the patient to be treated would be beneficial to aid in decisions regarding treatment personalization. The present study was conducted to create such a tool. On multivariate analysis, two pre-treatment factors, age and KPS, showed a trend or significant association regarding 1-year survival. Based on these factors, a scoring tool including three prognostic groups with significantly different survival rates was prepared. Patients who achieved 5 or 9 points (group A) had the worst 1-year survival probability, which was only 17%. In these patients, higher-dose longer-course programs may be overly aggressive and their administration should be very carefully considered. Patients of group B (10 points) had an intermediate prognosis. Longer-course radiotherapy programs with higher total doses and lower doses per fraction appear reasonable. Group C patients (14 points) had the most favorable prognosis with a 1-year survival probability of 82%. These patients should definitively be treated with higher-dose longer-course programs. The results of radiotherapy of locally recurrent carcinoma of the bladder may be improved with addition of concurrent chemotherapy analogous to primary bladder-preserving treatment (2-4). There is a hope that combinations of radiotherapy and new systemic treatments may provide better results (5-7, 21, 22).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Univariate survival analyses of the six evaluated pre-treatment factors.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan–Meier curves of the different patient scores.

In conclusion, this scoring tool, which is based on pre-treatment factors and includes three prognostic groups with different 1-year survival probabilities, can aid physicians who are treating patients with locally recurrent carcinoma of the urinary bladder.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier curves of the survival groups A (5-9 points), B (10 points) and C (14 points).

Footnotes

  • This article is freely accessible online.

  • Received January 17, 2017.
  • Revision received February 25, 2017.
  • Accepted March 1, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Jemal A,
    2. Siegel R,
    3. Ward E,
    4. Murray T,
    5. Xu J,
    6. Smigal C,
    7. Thun M
    : Cancer statistics, 2006. CA: a cancer journal for clinicians 56: 106-130, 2006.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Rodel C,
    2. Grabenbauer GG,
    3. Kühn R,
    4. Papadopoulos T,
    5. Dunst J,
    6. Meyer M,
    7. Schrott KM,
    8. Sauer R
    : Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061-3071, 2002.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Koga F,
    2. Kihara K
    : Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol 19: 388-401, 2012.
    OpenUrlPubMed
  4. ↵
    1. Weiss C,
    2. Wittlinger M,
    3. Engehausen DG,
    4. Krause FS,
    5. Ott OJ,
    6. Dunst J,
    7. Sauer R,
    8. Rodel C
    : Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 70: 1502-1506, 2008.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Jana BR,
    2. Zhou Y
    : Novel molecular targets for the therapy of urothelial cancer. Anticancer Res 35: 4557-4567, 2015.
    OpenUrlAbstract/FREE Full Text
    1. Lea MA,
    2. Guzman Y,
    3. Desbordes C
    : Inhibition of growth by combined treatment with inhibitors of lactate dehydrogenase and either phenformin or inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3. Anticancer Res 36: 1479-1488, 2016.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kuo JH,
    2. Shih TY,
    3. Lin JP,
    4. Lai KC,
    5. Lin ML,
    6. Yang MD,
    7. Chung JG
    : Cantharidin induces DNA damage and inhibits DNA repair-associated protein expressions in TSGH8301 human bladder cancer cell. Anticancer Res 35: 795-804, 2015.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Rades D,
    2. Schild SE,
    3. Bajrovic A,
    4. Janssen S,
    5. Bartscht T
    : In vivo personalized radiotherapeutic approaches for elderly patients with epidural cord compression from gastric cancer. In Vivo 30: 69-72, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Seidl D,
    2. Janssen S,
    3. Strojan P,
    4. Bajrovic A,
    5. Schild SE,
    6. Rades D
    : Prognostic factors after definitive radio(chemo)therapy of locally advanced head and neck cancer. Anticancer Res 36: 2523-2526, 2016.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kaesmann L,
    2. Janssen S,
    3. Schild SE,
    4. Rades D
    : Value of comorbidity scales for predicting survival after radiochemotherapy of small cell lung cancer. Lung 194: 295-298, 2016.
    OpenUrlPubMed
  9. ↵
    1. Rades D,
    2. Käsmann L,
    3. Schild SE,
    4. Janssen S
    : A survival score for patients receiving palliative irradiation for locally advanced lung cancer. Clin Lung Cancer 17: 558-562, 2016.
    OpenUrl
    1. Douglas S,
    2. Schild SE,
    3. Rades D
    : A new score predicting the survival of patients with spinal cord compression from myeloma. BMC Cancer 12: 425, 2012.
    OpenUrlPubMed
    1. Dziggel L,
    2. Segedin B,
    3. Podvrsnik NH,
    4. Oblak I,
    5. Schild SE,
    6. Rades D
    : Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189: 364-366, 2013.
    OpenUrlPubMed
    1. Rades D,
    2. Hueppe M,
    3. Schild SE
    : A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. Cancer 119: 897-903, 2013.
    OpenUrlPubMed
    1. Rades D,
    2. Dziggel L,
    3. Nagy V,
    4. Segedin B,
    5. Lohynska R,
    6. Veninga T,
    7. Khoa MT,
    8. Trang NT,
    9. Schild SE
    : A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiother Oncol 108: 123-127, 2013.
    OpenUrlPubMed
    1. Bolm L,
    2. Janssen S,
    3. Käsmann L,
    4. Wellner U,
    5. Bartscht T,
    6. Schild SE,
    7. Rades D
    : Predicting survival after irradiation of metastases from pancreatic cancer. Anticancer Res 35: 4105-4108, 2015.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Janssen S,
    2. Dahlke M,
    3. Trang NT,
    4. Khoa MT,
    5. Rades D
    : Estimation of the six-month survival probability after radiosurgery for brain metastases from kidney vancer. Anticancer Res 35: 4215-4217, 2015.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Rades D,
    2. Huttenlocher S,
    3. Gebauer N,
    4. Hornung D,
    5. Trang NT,
    6. Khoa MT,
    7. Schild SE
    : Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Res 35: 3571-3574, 2015.
    OpenUrlAbstract/FREE Full Text
    1. Rades D,
    2. Panzner A,
    3. Dziggel L,
    4. Haatanen T,
    5. Lohynska R,
    6. Schild SE
    : Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 118: 3853-3859, 2012.
    OpenUrl
  12. ↵
    1. Rades D,
    2. Huttenlocher S,
    3. Rudat V,
    4. Hornung D,
    5. Blanck O,
    6. Phuong PC,
    7. Khoa MT,
    8. Schild SE,
    9. Fischer D
    : Radiosurgery with 20 Gy provides better local contol of 1-3 brain metastases from breast cancer than with lower doses. Anticancer Res 35: 333-336, 2015.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kilari D,
    2. Iczkowski KA,
    3. Pandya C,
    4. Robin AJ,
    5. Messing EM,
    6. Guancial E,
    7. Kim ES
    : Copper transporter-CTR1 expression and pathological outcomes in platinum-treated muscle-invasive bladder cancer patients. Anticancer Res 36: 495-501, 2016.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Nakagawa YU,
    2. Nagaya H,
    3. Miyata T,
    4. Wada Y,
    5. Oyama T,
    6. Gotoh A
    : Piperazine-based alpha-1 AR blocker, naftopidil, selectively suppresses malignant human bladder cells via induction of apoptosis. Anticancer Res 36: 1563-1570, 2016.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

In Vivo
Vol. 31, Issue 3
May-June 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder
LISA MANIG, STEFAN JANSSEN, STEVEN E SCHILD, DIRK RADES
In Vivo May 2017, 31 (3) 435-438;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder
LISA MANIG, STEFAN JANSSEN, STEVEN E SCHILD, DIRK RADES
In Vivo May 2017, 31 (3) 435-438;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder
  • A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer
  • Google Scholar

More in this TOC Section

  • Validation of the Chick Chorioallantoic Membrane (CAM) Model for Biocompatibility Analysis of Biomaterials in the Context of the 3R-cascade: A Pilot Study
  • Immersive Virtual Reality for Reducing Intraoperative Pain: A Pilot Randomized Controlled Trial
  • First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10BPA
Show more Clinical Studies

Similar Articles

Keywords

  • Locally recurrent carcinoma of the bladder
  • irradiation
  • pre-treatment factors
  • predictive score
  • survival
In Vivo

© 2025 In Vivo

Powered by HighWire